GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 26, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table provides a rollforward of the Company’s goodwill:


			Adjustments to Goodwill						Adjustments to Goodwill
	December 29, 2018		Acquisitions		Foreign Exchange		December 28, 2019		Acquisitions		Foreign Exchange		December 26, 2020
	(in thousands)
RMS	$	56,968	$	—	$	(382)	$	56,586	$	229,654	$	1,519	$	287,759
DSA	2,056,470		293,380		373		2,350,223		(629)		33,536		2,383,130
Manufacturing	138,695		—		61		138,756		—		4,523		143,279
Gross carrying amount	2,252,133		293,380		52		2,545,565		229,025		39,578		2,814,168
Accumulated impairment loss - DSA	(1,005,000)		—		—		(1,005,000)		—		—		(1,005,000)
Goodwill	$	1,247,133					$	1,540,565					$	1,809,168

Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2020, 2019 and 2018, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired.

The increase in goodwill during fiscal year 2020 related primarily to the acquisitions of HemaCare and Cellero in the RMS reportable segment. The increase in goodwill during fiscal year 2019 related primarily to the acquisition of Citoxlab in the DSA reportable segment.

Intangible Assets, Net

The following table displays intangible assets, net by major class:


	December 26, 2020						December 28, 2019
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
	(in thousands)
Backlog	$	29,233	$	(29,233)	$	—	$	28,865	$	(26,895)	$	1,970
Technology	130,907		(81,305)		49,602		122,106		(57,737)		64,369
Trademarks and trade names	15,870		(5,648)		10,222		8,430		(4,901)		3,529
Other	20,903		(14,633)		6,270		18,279		(12,307)		5,972
Other intangible assets	196,913		(130,819)		66,094		177,680		(101,840)		75,840
Client relationships	1,137,331		(415,826)		721,505		934,668		(321,095)		613,573
Intangible assets	$	1,334,244	$	(546,645)	$	787,599	$	1,112,348	$	(422,935)	$	689,413

The increase in intangible assets, net during fiscal year 2020 related primarily to the acquisitions of HemaCare and Cellero.

Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2020, 2019 and 2018 was $111.9 million, $89.5 million and $64.8 million, respectively. As of December 26, 2020, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows:


Fiscal Year	Amortization Expense
	(in thousands)
2021	$	104,272
2022	91,877
2023	83,651
2024	76,291
2025	71,915